健脾疏肝方对非酒精性脂肪性肝炎大鼠胰岛素抵抗的影响

姜慧; 李军祥; 韩海啸; 邢韵淇; 许冰; 王超; 张昔伟

doi:10.3969/j.issn.1671-038X.2021.07.01

健脾疏肝方对非酒精性脂肪性肝炎大鼠胰岛素抵抗的影响

- 1. 北京中医药大学(北京, 100029);
- 2. 北京中医药大学东方医院脾胃肝胆科;
- 3. 北京中医药大学东方医院B超室;
- 4. 北京市大兴区中西医结合医院消化内科
基金项目:
北京中医药新奥奖励基金课题（No：2017-XAJLJJ-019）；国家自然科学基金（No：81503549）；北京市自然科学基金（No：7202124）；中医药传承与创新"百千万"人才工程（岐黄工程）岐黄学者项目[No：国中医药人教发（2018）12号]

详细信息

通讯作者: 张昔伟,E-mail:zhangxiwei1993@163.com

中图分类号: R575.1

收稿日期: 2020-12-26

Effect of Jianpi Shugan Decoction on insulin resistance in rats with nonalcoholic steatohepatitis

- 1. Beijing University of Chinese Medicine, Beijing, 100029, China;
- 2. Department of Spleen, Stomach, Liver and Gallbladder, Dongfang Hospital of Beijing University of Chinese Medicine;
- 3. B-ultrasound Room, Dongfang Hospital of Beijing University of Chinese Medicine;
- 4. Department of Gastroenterology, Daxing District Hospital of Integrated Chinese and Western Medicine

More Information

Corresponding author: ZHANG Xiwei, E-mail: zhangxiwei1993@163.com

Received Date: 26 December 2020

摘要

摘要: 目的：观察健脾疏肝方对非酒精性脂肪性肝炎（NASH）大鼠胰岛素抵抗的影响，并探讨其作用机制。方法：40只SD雄性大鼠中随机选择34只给予高脂饲料建立NASH模型，其余6只大鼠作为正常组喂食普通饲料。将NASH造模成功后的大鼠随机分为模型组、健脾疏肝方低、中、高剂量组、多烯磷脂酰胆碱（易善复）组。模型组和正常组给予去离子水灌胃，中药各实验组给予健脾疏肝方低、中、高剂量颗粒剂灌胃，易善复组给予易善复混悬液灌胃，1次/d，连续干预4周。测定各组大鼠给药后的体重、血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、血清甘油三脂（TG）、血清胆固醇（TC）水平，测定血清脂联素（ADPN）、空腹血糖（FPG）、血清胰岛素（FINS）水平，计算胰岛素抵抗指数（HOMA-IR），计算肝脏指数（肝湿重/总体重×100%），苏木精-伊红染色和油红O染色观察肝脏组织病理变化。结果：正常组及各实验组大鼠的体重均低于模型组，差异有统计学意义（P<0.05）。健脾疏肝方中、高剂量组及易善复组血清ALT、AST水平较模型组显著降低，健脾疏肝方低、中剂量组血清TC水平较模型组显著降低，健脾疏肝方高剂量组血清TG水平较模型组显著降低，差异有统计学意义（P<0.05）。健脾疏肝方中、高剂量组及易善复组ADPN水平均高于模型组，差异有统计学意义（P<0.05）。健脾疏肝方中、高剂量组FPG、FINS、HOMA-IR均高于正常组，低于模型组，健脾疏肝方低剂量组HOMA-IR低于模型组，易善复组FINS、HOMA-IR低于模型组，均差异有统计学意义（P<0.05）。结论：健脾疏肝方能有效改善NASH大鼠的肝酶、肝脂、FPG、FINS，降低HOMA-IR，升高ADPN，从而起到调节脂质代谢，减轻胰岛素抵抗的作用。
- 非酒精性脂肪性肝炎 /
- 高脂饮食 /
- 健脾疏肝方 /
- 胰岛素抵抗 /
- 大鼠
Abstract: Objective: To observe the effect of Jianpi Shugan Decoction on insulin resistance in rats with nonalcoholic steatohepatitis(NASH) and explore its mechanism. Methods: Thirty four male SD rats were randomly selected and fed with high-fat diet to establish NASH model, and the other 6 rats were fed with normal diet as normal group. The rats were randomly divided into model group, Jianpi Shugan Decoction low, medium and high dose groups, polyene phosphatidylcholine(yishanfu) group. The model group and normal group were given deionized water by gavage, the experimental groups of Traditional Chinese Medicine were given Jianpi Shugan Decoction low, medium and high dose granules, and the yishanfu group was given yishanfu suspension by gavage, once a day for 4 weeks. The body weight, serum alanine aminotransferase(ALT), aspartate aminotransferase(AST), serum triglyceride(TG), serum cholesterol(TC), adiponectin(ADPN), fasting plasma glucose(FPG), serum insulin(FINS) were measured, and the insulin resistance index(HOMA) was calculated assessment for insulin resistance(HOMA-IR), liver index(liver wet weight/total weight × 100%), HE and oil red O staining were used to observe the pathological changes of liver tissue. Results: The body weight of normal group and each experimental group was lower than that of model group(P<0.05). The serum levels of ALT and AST in the middle and high dose groups of Jianpi Shugan Decoction and yishanfu group were significantly lower than those of the model group, the serum TC level of the low and middle-dose groups of Jianpi Shugan Decoction was significantly lower than that of the model group, and the serum TG level of the high-dose Jianpi Shugan Decoction group was significantly lower than that of the model group(P<0.05). The average ADPN level of Jianpi Shugan Decoction group was higher than that of model group(P<0.05). The levels of FPG, FINS and HOMA-IR in the middle and high dose groups of Jianpi Shugan Decoction were higher than those in the normal group and lower than those in the model group. The levels of HOMA-IR in the low-dose Jianpi Shugan Decoction group were lower than those in the model group, and the levels of fins and HOMA-IR in the yishanfu group were lower than those in the model group(P<0.05). Conclusion: Jianpi Shugan Decoction can effectively improve liver enzymes, liver fat, FPG, FINS, reduce HOMA-IR and increase ADPN, thus regulating lipid metabolism and reducing insulin resistance.
- nonalcoholic steatohepatitis /
- high fat diet /
- Jianpi Shugan Decoction /
- insulin resistance /
- rats

HTML全文

参考文献(25)

[1]	European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol, 2016, 64(6):1388-1402.
[2]	Younossi ZM.Non-alcoholic fatty liver disease-A global public health perspective[J].J Hepatol, 2019, 70(3):531-544.
[3]	Younossi Z, Tacke F, Arrese M, et al.Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis[J].Hepatology, 2019, 69(6):2672-2682.
[4]	Sheka AC, Adeyi O, Thompson J, et al.Nonalcoholic Steatohepatitis:A Review[J].JAMA, 2020, 323(12):1175-1183.
[5]	Younossi ZM, Koenig AB, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64(1):73-84.
[6]	Wu Y, Zheng Q, Zou B, et al.The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product:a meta-analysis[J].Hepatol Int, 2020, 14(2):259-269.
[7]	Michelotti GA, Machado MV, Diehl AM.NAFLD, NASH and liver cancer[J].Nat Rev Gastroenterol Hepatol, 2013, 10(11):656-65.
[8]	Khan RS, Bril F, Cusi K, et al.Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease[J].Hepatology, 2019, 70(2):711-724.
[9]	Stefan N, Häring HU, Cusi K.Non-alcoholic fatty liver disease:causes, diagnosis, cardiometabolic consequences, and treatment strategies[J].Lancet Diabetes Endocrinol, 2019, 7(4):313-324.
[10]	Fujii H, Kawada N, Japan Study Group of Nafld Jsg-Nafld.The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease[J].Int J Mol Sci, 2020, 21(11):3863.
[11]	谢添弘, 陈润花, 毛堂友, 等.李军祥教授治疗非酒精性脂肪性肝炎临床经验[J].中国中西医结合消化杂志, 2018, 26(8):698-700.
[12]	李军祥, 王允亮, 刘敏, 等.健脾疏肝方治疗非酒精性脂肪性肝炎多中心、随机、对照的临床研究[J].中国中西医结合杂志, 2014, 34(1):15-19.
[13]	赵伟, 孙国志.不同种实验动物间用药量换算[J].畜牧兽医科技信息, 2010, 12(5):52-53.
[14]	Kleiner DE, Brunt EM, Van Natta M, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J].Hepatology, 2005, 41(6):1313-1321.
[15]	Wang XJ, Malhi H.Nonalcoholic Fatty Liver Disease[J].Ann Intern Med, 2018, 169(9):ITC65-ITC80.
[16]	Stefan N, Häring HU, Cusi K.Non-alcoholic fatty liver disease:causes, diagnosis, cardiometabolic consequences, and treatment strategies[J].Lancet Diabetes Endocrinol, 2019, 7(4):313-324.
[17]	李丹, 李异玲.非酒精性脂肪性肝病发病机制及治疗进展[J].实用药物与临床, 2017, 20(11):1340-1343.
[18]	刘晓燕, 高卉.非酒精性脂肪性肝病的研究进展[J].湖北科技学院学报(医学版), 2019, 33(4):364-368.
[19]	Khan RS, Bril F, Cusi K, et al.Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease[J].Hepatology, 2019, 70(2):711-724.
[20]	Lonardo A, Nascimbeni F, Maurantonio M, et al.Nonalcoholic fatty liver disease:Evolving paradigms[J].World J Gastroenterol, 2017, 23(36):6571-6592.
[21]	Wattacheril J, Chalasani N.Nonalcoholic fatty liver disease(NAFLD):is it really a serious condition?[J].Hepatology, 2012, 56(4):1580-1584.
[22]	Friedman SL, Neuschwander-Tetri BA, Rinella M, et al.Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med, 2018, 24(7):908-922.
[23]	Bessone F, Razori MV, Roma MG.Molecular pathways of nonalcoholic fatty liver disease development and progression[J].Cell Mol Life Sci, 2019, 76(1):99-128.
[24]	Asrih M, Jornayvaz FR.Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance[J].J Endocrinol, 2013, 218(3):25-36.
[25]	Samuel VT, Shulman GI.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases[J].Cell Metab, 2018, 27(1):22-41.